Is a 4.6 mm left distal ureteral stone at the S1 level with 697 HU attenuation and minimal left hydroureter an indication for ureteroscopy with laser lithotripsy and double‑J stent placement?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 15, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of 4.6 mm Distal Ureteral Stone

A 4.6 mm left distal ureteral stone at the S1 level with minimal hydroureter should be managed initially with conservative medical expulsive therapy (alpha-blocker plus NSAID) for 4–6 weeks, not immediate ureteroscopy with laser lithotripsy and DJ stent placement. 1, 2

Initial Conservative Management is Indicated

For uncomplicated ureteral stones ≤10 mm, medical expulsive therapy (MET) is the recommended first-line approach. 1, 2 Your stone at 4.6 mm falls well within this range and should be given a trial of conservative management before proceeding to surgical intervention.

Why Conservative Management First?

  • Stones 2–4 mm pass spontaneously in 83% of cases, with an average passage time of 12.2 days, and only 17% require intervention. 3
  • Stones 4–6 mm pass spontaneously in approximately 50% of cases, with an average passage time of 22.1 days. 3
  • For 95% of stones 2–4 mm to pass, it takes up to 40 days. 3
  • Distal stone location (as in your case at S1 level) is associated with higher spontaneous passage rates compared to proximal stones. 3

Appropriate Conservative Management Protocol

Prescribe an alpha-blocker (tamsulosin) combined with an NSAID for pain control. 4, 1 Patients must be counseled that alpha-blockers are used off-label for this indication, with potential side effects including orthostatic hypotension, dizziness, and retrograde ejaculation. 1

Conservative management requires:

  • Well-controlled pain with oral analgesics 1
  • No clinical evidence of sepsis or infection 1
  • Adequate renal function 1
  • Maximum duration of 4–6 weeks from initial presentation 1, 2, 5

Mandatory monitoring with periodic imaging (low-dose CT or renal ultrasound) is required to track stone position and assess for progression of hydronephrosis. 1

When to Proceed with Ureteroscopy and Laser Lithotripsy

Immediate ureteroscopy with DJ stent is NOT indicated unless:

Absolute Indications for Urgent Intervention

  • Sepsis or urinary tract infection with obstruction (requires urgent decompression via percutaneous nephrostomy or ureteral stenting first, NOT immediate stone removal) 1, 2, 6
  • Anuria in an obstructed kidney 1, 5
  • Intractable pain despite medical management 5
  • Solitary kidney or bilateral obstruction 5

Indications for Elective Ureteroscopy After Conservative Trial

  • Failed conservative management after 4–6 weeks 1, 2, 5
  • Uncontrolled pain despite optimal medical therapy 1
  • Development of fever or signs of infection 1
  • Progressive hydronephrosis or declining renal function 5
  • Stone growth on follow-up imaging 5

Your Specific Case Analysis

Your stone presents with "minimal left sided hydroureter" only, which does not constitute an absolute indication for immediate intervention. 7 The high attenuation value (697 HU) suggests a calcium-based stone, which responds well to both conservative management and ureteroscopy if needed later. 4

If ureteroscopy becomes necessary after failed conservative management:

  • Ureteroscopy with holmium laser lithotripsy achieves 90–95% stone-free rates for stones <10 mm in a single session. 2
  • Routine pre-operative ureteral stenting is NOT recommended, as successful access is achievable on the initial attempt in most cases. 4, 2
  • Post-operative DJ stent placement is NOT routinely required after uncomplicated ureteroscopy, but may be considered based on intra-operative findings (ureteral injury, stricture, or planned secondary procedure). 4, 2

Critical Pitfalls to Avoid

Do not delay intervention beyond 6 weeks if conservative management fails, as this risks irreversible kidney damage. 1, 2, 5

Do not proceed with definitive stone treatment if infection develops—drain first with percutaneous nephrostomy or ureteral stent, treat infection with antibiotics, then address the stone definitively once infection resolves. 2, 6

Do not use alpha-blockers in patients with sepsis or significant obstruction requiring urgent decompression. 1

Obtain urine culture before any procedure and treat bacteriuria; antibiotic prophylaxis is mandatory for ureteroscopy but not for conservative management in low-risk patients. 2

References

Guideline

Medical Management of Ureteral Stones

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Treatment Guidelines for Renal and Ureteric Calculi

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Indications for Active Stone Removal

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

Can a 4 mm kidney stone pass through the ureters?
How to manage a patient with a 0.3 cm obstructing calculus in the ureter and associated hydroureter?
Can a 5mm kidney stone pass on its own?
Can a 6mm kidney stone pass on its own without medical supervision?
What is the recommended initial approach for an elderly patient with a 9.2 mm proximal ureteric calculus obstruction causing right hydrouretero nephrosis?
For an adult with seropositive moderate‑to‑severe systemic lupus erythematosus inadequately controlled on antimalarials, low‑dose glucocorticoids, or conventional immunosuppressants, what are the indications, contraindications, dosing regimens (IV 10 mg/kg on days 0, 14, 28 then every 28 days; SC 200 mg weekly after loading doses on days 0, 7, 14), monitoring requirements, criteria for discontinuation, and alternative therapies?
What is the mechanism of action of belimumab (IgG1λ (Immunoglobulin G1 lambda) monoclonal antibody) in adults with seropositive moderate-to-severe systemic lupus erythematosus (SLE) refractory to antimalarials, low-dose glucocorticoids, or conventional immunosuppressants?
What are the recommended clinical guidelines for initiating and titrating leucovorin rescue in patients receiving high‑, intermediate‑, or low‑dose methotrexate, including adjustments for impaired renal function, when a FRATT test is unavailable?
In a diabetic patient with thyroid carcinoma, does the cancer affect insulin therapy and require dose adjustments?
What are the typical presentation, complications, and management of primary Epstein‑Barr virus infection (infectious mononucleosis) in an 11‑year‑old child?
What is the optimal clinical plan to initiate leucovorin (folinic acid) in a young, non‑verbal child with autism spectrum disorder when parents request treatment and the folate‑receptor autoantibody (FRAT) test is unavailable?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.